Efficacy and safety of dupilumab for moderate‐to‐severe atopic dermatitis: a systematic review for the EAACI Biologicals Guidelines

Ioana Agache, Yang Song, Margarita Posso, Pablo Alonso‐coello, Claudio Rocha, Ivan Solà, Jessica Beltran, Cezmi Akdis, Mubeccel Akdis, Knut Brockow, Tomas Chivato, Stefano Del Giacco, Thomas Eiwegger, Kilian Eyerich, Ana Giménez‐arnau, Jan Gutermuth, Emma Guttman‐yassky, Marcus Maurer, Graham Ogg, Peck Y. OngLiam O’mahony, Jürgen Schwarze, Thomas Werfel, Carlos Canelo‐aybar, Oscar Palomares, Marek Jutel

Research output: Contribution to journalArticlepeer-review

Abstract

This systematic review evaluates the efficacy, safety and economic impact of dupilumab compared to standard of care for uncontrolled moderate-to-severe atopic dermatitis (AD). Pubmed, EMBASE and Cochrane Library were searched for RCTs and health economic evaluations. Critical and important AD-related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE. Seven RCTs including 1845 subjects > 12 years treated with dupilumab 16 to 52 weeks were evaluated. For adults there is high certainty that dupilumab decreases SCORAD (MD -30,72; 95%CI -34,65% to -26,79%) and EASI-75 (RR 3.09; 95%CI 2.45 to 3.89), pruritus (RR 2.96; 95%CI 2.37 to 3.70), rescue medication (RR 3.46; 95%CI 2.79 to 4.30), sleep disturbance (MD -7.29; 95%CI -8.23 to -6.35), anxiety/depression (MD -3.08; 95% CI -4.41 to -1.75) and improves quality of life (MD -4.80; 95% CI -5.55 to -4.06). The efficacy for adolescents is similar. Dupilumab-related adverse events (AEs) slightly increase (low certainty). The evidence for dupilumab-related serious AE is uncertain. The incremental cost-effectiveness ratio ranged from 28,500 £ (low certainty) to 124,541 US$ (moderate certainty). More data on long term safety are needed both for children and adults, together with more efficacy data in the paediatric population. Registration: PROSPERO (CRD42020153645).
Original languageEnglish
JournalAllergy
DOIs
Publication statusPublished - 21 Jul 2020

Fingerprint

Dive into the research topics of 'Efficacy and safety of dupilumab for moderate‐to‐severe atopic dermatitis: a systematic review for the EAACI Biologicals Guidelines'. Together they form a unique fingerprint.

Cite this